Targeted therapy combination shows superior outcomes in advanced kidney cancer Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.
https://www.news-medical.net/n....ews/20251018/Targete